MarketCapExport financials
Halozyme Therapeutics (HALO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Halozyme Therapeutics Balance Sheet 2025-2008 | HALO
Brief overview of Halozyme Therapeutics's assets and capital
This overview follows the five latest available annual observations between 2019 and 2025.
Assets reached $2.5 billion, compared with $565.9 million at the beginning. Growth of +346.3% and CAGR near 28.3% show active expansion.
Funding shifted toward liabilities: they gained +422.4%, compared with +346.3% for assets.
Internal capital represents 1.9% of the balance sheet versus 16.2% five periods ago. The cushion is thin.
Net debt to equity is high at 41.15x; refinancing risk and borrowing costs become more important.
Cash accounts for 5.3% of assets versus 21.2% initially. The change indicates the degree of financial flexibility.
Accumulated earnings ended at $54.8 million, a change of +109.1%. They remain an important part of the capital base.
Overall picture
Halozyme Therapeutics's balance sheet profile remains vulnerable. Lower liabilities and capital accumulation are the main routes to improvement.
Annual Balance Sheet Halozyme Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
2.01 B | 1.39 B | 1.38 B | 1.27 B | 758 M | 646 M | 282 M | 68.4 M | 33.6 M | 150 M | 6.54 M | 62.7 M | 66.6 M | -68.8 M | -52.8 M | - | - | - |
Long Term Debt |
2.14 B | 1.51 B | 1.5 B | 1.49 B | 787 M | 397 M | 383 M | 34.9 M | 125 M | 199 M | 28 M | 49.9 M | 49.8 M | 29.7 M | - | - | - | - |
Long Term Debt Current |
- | - | - | 13.3 M | 89.4 M | 397 M | 19.5 M | 91.5 M | 77.2 M | 17.4 M | 21.9 M | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 388 M | 42 M | 180 M | 239 M | 76.3 M | 100 M | 96.3 M | 66.9 M | 37.6 M | - | - | - |
Total Current Liabilities |
177 M | 139 M | 112 M | 131 M | 117 M | 421 M | 85.6 M | 149 M | 131 M | 54.6 M | 62.5 M | 24.3 M | 25.5 M | 18.9 M | 17.3 M | 15.3 M | - | - |
Total Liabilities |
2.48 B | 1.7 B | 1.65 B | 1.67 B | - | - | 474 M | 191 M | 312 M | 294 M | 139 M | 125 M | 122 M | 85.9 M | 54.9 M | - | - | - |
Deferred Revenue |
- | - | - | 3.25 M | - | 1.75 M | 4.01 M | 4.25 M | 6.57 M | 4.79 M | 9.3 M | 7.37 M | 7.4 M | 8.89 M | 4.13 M | 2.92 M | - | - |
Retained Earnings |
54.8 M | 360 M | 90.6 M | 143 M | -58.9 M | -475 M | -604 M | -531 M | -522 M | -585 M | -483 M | -450 M | -382 M | -299 M | -245 M | -225 M | - | - |
Total Assets |
2.53 B | 2.06 B | 1.73 B | 1.84 B | 1.1 B | 580 M | 566 M | 440 M | 520 M | 262 M | 182 M | 166 M | 102 M | 135 M | 65.8 M | 91.3 M | - | - |
Cash and Cash Equivalents |
134 M | 116 M | 118 M | 234 M | 119 M | 148 M | 120 M | 57.9 M | 169 M | 66.8 M | 43.3 M | 61.4 M | 27.4 M | 99.5 M | 52.4 M | 82.8 M | 67.5 M | 63.7 M |
Book Value |
48.8 M | 364 M | 83.8 M | 170 M | 1.1 B | 580 M | 91.8 M | 249 M | 208 M | -32.5 M | 43 M | 41.4 M | -20 M | 48.9 M | 10.9 M | 91.3 M | - | - |
Total Shareholders Equity |
48.8 M | 364 M | 83.8 M | 170 M | 197 M | 151 M | 91.8 M | 249 M | 208 M | -32.5 M | 43 M | 41.4 M | -20 M | 48.9 M | 10.9 M | 20.4 M | 6.9 M | 15.4 M |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Halozyme Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
1.94 B | 1.94 B | 800 M | 1.51 B | 1.51 B | 1.51 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.49 B | 1.49 B | 1.49 B | 1.15 B | 788 M | 787 M | 786 M | 786 M | 785 M | - | - | - | - | 383 M | 383 M | 383 M | 383 M | 34.9 M | 34.9 M | 34.9 M | 34.9 M | 125 M | 125 M | 125 M | 125 M | 199 M | 199 M | 199 M | 199 M | 28 M | 28 M | 28 M | 28 M | 49.9 M | 49.9 M | 49.9 M | 49.9 M | 49.8 M | 49.8 M | 49.8 M | 49.8 M | 29.7 M | 29.7 M | 29.7 M | 29.7 M | - | - | - | - |
Total Liabilities |
2.43 B | 2.45 B | 1.72 B | 1.72 B | 1.71 B | 1.7 B | 1.67 B | 1.68 B | 1.66 B | 1.65 B | 1.64 B | 1.66 B | 1.63 B | 1.67 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | 667 K | 842 K | 3.25 M | 3.25 M | 3.59 M | 4.13 M | 1.75 M | 1.75 M | 2.24 M | 1.25 M | 1.75 M | 1.75 M | 748 K | 1.75 M | 1.75 M | 4.01 M | 4.01 M | 4.01 M | 4.01 M | 4.25 M | 4.25 M | 4.25 M | 1.25 M | 6.57 M | 6.57 M | 6.57 M | 6.57 M | 4.79 M | 4.79 M | 4.79 M | 4.79 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 7.37 M | 7.37 M | 7.37 M | 7.37 M | 7.4 M | 7.4 M | 7.4 M | 7.4 M | 8.89 M | 8.89 M | 8.89 M | 8.89 M | 4.13 M | 4.13 M | 4.13 M | 4.13 M |
Retained Earnings |
151 M | 205 M | 502 M | 361 M | 478 M | 360 M | 398 M | 261 M | 167 M | 90.6 M | 222 M | 140 M | 65.7 M | 143 M | 85.5 M | 23.9 M | 1.2 M | -58.9 M | -126 M | -342 M | -434 M | -475 M | -475 M | -475 M | -475 M | -604 M | -604 M | -604 M | -604 M | -531 M | -531 M | -531 M | -531 M | -522 M | -522 M | -522 M | -522 M | -585 M | -585 M | -585 M | -585 M | -483 M | -483 M | -483 M | -483 M | -450 M | -450 M | -450 M | -450 M | -382 M | -382 M | -382 M | -382 M | -299 M | -299 M | -299 M | -299 M | -245 M | -245 M | -245 M | -245 M |
Total Assets |
2.58 B | 2.67 B | 2.22 B | 2.05 B | 2.2 B | 2.06 B | 2.12 B | 1.97 B | 1.84 B | 1.73 B | 1.89 B | 1.81 B | 1.7 B | 1.84 B | 1.86 B | 1.78 B | 1.16 B | 1.1 B | 1.19 B | 1.03 B | 967 M | 580 M | 580 M | 580 M | 580 M | 566 M | 566 M | 566 M | 566 M | 440 M | 440 M | 440 M | 440 M | 520 M | 520 M | 520 M | 520 M | 262 M | 262 M | 262 M | 262 M | 182 M | 182 M | 182 M | 182 M | 166 M | 166 M | 166 M | 166 M | 102 M | 102 M | 102 M | 102 M | 135 M | 135 M | 135 M | 135 M | 65.8 M | 65.8 M | 65.8 M | 65.8 M |
Cash and Cash Equivalents |
163 M | 310 M | 420 M | 61.9 M | 176 M | 116 M | 154 M | 188 M | 165 M | 118 M | 274 M | 221 M | 96.9 M | 234 M | 148 M | 91.4 M | 118 M | 119 M | 492 M | 447 M | 499 M | 148 M | 148 M | 148 M | 148 M | 120 M | 120 M | 120 M | 120 M | 57.9 M | 57.9 M | 57.9 M | 57.9 M | 169 M | 169 M | 169 M | 169 M | 66.8 M | 66.8 M | 66.8 M | 66.8 M | 43.3 M | 43.3 M | 43.3 M | 43.3 M | 61.4 M | 61.4 M | 61.4 M | 61.4 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 99.5 M | 99.5 M | 99.5 M | 99.5 M | 52.4 M | 52.8 M | 52.8 M | 52.8 M |
Book Value |
144 M | 220 M | 504 M | 333 M | 482 M | 364 M | 453 M | 289 M | 178 M | 83.8 M | 249 M | 151 M | 65.8 M | 170 M | 1.86 B | 1.78 B | 1.16 B | 1.1 B | 1.19 B | 1.03 B | 967 M | 580 M | 580 M | 580 M | 580 M | 566 M | 566 M | 566 M | 566 M | 440 M | 440 M | 440 M | 440 M | 520 M | 520 M | 520 M | 520 M | 262 M | 262 M | 262 M | 262 M | 182 M | 182 M | 182 M | 182 M | 166 M | 166 M | 166 M | 166 M | 102 M | 102 M | 102 M | 102 M | 135 M | 135 M | 135 M | 135 M | 65.8 M | 65.8 M | 65.8 M | 65.8 M |
Total Shareholders Equity |
144 M | 220 M | 504 M | 333 M | 482 M | 364 M | 453 M | 289 M | 178 M | 83.8 M | 249 M | 151 M | 65.8 M | 170 M | 97 M | 293 M | 260 M | 197 M | 282 M | 120 M | 67.6 M | 151 M | 151 M | 151 M | 151 M | 91.8 M | 91.8 M | 91.8 M | 91.8 M | 249 M | 249 M | 249 M | 249 M | 208 M | 208 M | 208 M | 208 M | -32.5 M | -32.5 M | -32.5 M | -32.5 M | 43 M | 43 M | 43 M | 43 M | 41.4 M | 41.4 M | 41.4 M | 41.4 M | -20 M | -20 M | -20 M | -20 M | 48.9 M | 48.9 M | 48.9 M | 48.9 M | 10.9 M | 10.9 M | 10.9 M | 10.9 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Halozyme Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Britain
USA
Schweiz
Canada
Danmark
